| 季从飞,苏小琴,倪婷婷,于 洋,陈 佳.免疫检查点抑制剂联合抗血管生成二线治疗晚期食管癌患者疗效及肿瘤标志物表达、预后生存期的影响[J].,2023,(22):4375-4379 |
| 免疫检查点抑制剂联合抗血管生成二线治疗晚期食管癌患者疗效及肿瘤标志物表达、预后生存期的影响 |
| Effect of Immune Checkpoint Inhibitors Combined with Anti-angiogenesis Second-line Treatment on Efficacy, Tumor Marker Expression and Prognosis of Patients with Advanced Esophageal Cancer |
| 投稿时间：2023-04-24 修订日期：2023-05-18 |
| DOI：10.13241/j.cnki.pmb.2023.22.035 |
| 中文关键词: 晚期食管癌 信迪利单抗 阿帕替尼 二线治疗 临床疗效 肿瘤标志物 预后生存期 |
| 英文关键词: Advanced esophageal cancer Sindilumab Apatinib Second-line treatment Clinical efficacy Tumor markers Prognostic survival |
| 基金项目:江苏省卫健委面上项目（M2022007）；江苏省南通市科技局项目（JCZ21068） |
|
| 摘要点击次数: 406 |
| 全文下载次数: 316 |
| 中文摘要: |
| 摘要 目的：研究信迪利单抗与阿帕替尼在晚期食管癌二线治疗中的应用效果。方法：根据随机数字表法将2019年1月～2022年1月本院收治的70例食管癌患者分为对照组与观察组，每组各35例，对照组给予阿帕替尼治疗，观察组给予信迪利单抗与阿帕替尼联合治疗，观察两组患者的客观缓解率（ORR）、疾病控制率（DCR），并在治疗前后利用酶联免疫吸附法检测其糖类抗原50（CA-50）、糖类抗原199（CA199）、癌胚抗原（CEA）、鳞癌抗原（SCC）水平；随后通过随访记录两组患者的预后生存期，并建立多因素Logistic模型分析影响患者达到中位OS、PFS的独立危险因素。结果：与对照组比较，观察组ORR、DCR率较高（P＜0.05）。与对照组相比，治疗后观察组血清CA50、CA199、CEA、SCC水平较低（P＜0.05）。与对照组比较，观察组中位OS、PFS较长（P＜0.05）。多因素Logistic分析结果显示，治疗方法、CA50、CA199、CEA、SCC是影响食管癌预后生存期的独立危险因素（P＜0.05）。结论：利用免疫检查点抑制剂与抗血管生成药物对晚期食管癌患者开展二线治疗，不仅能降低血清中的肿瘤标志物浓度，还能延长患者的预后生存期，治疗效果较为显著。 |
| 英文摘要: |
| ABSTRACT Objective: To study the application effect of sintilimab and apatinib in the second-line treatment of advanced esophageal cancer. Methods: According to the random number table method, 70 patients with esophageal cancer admitted to our hospital from January 2019 to January 2022 were divided into control group and observation group, 35 patients in each group, The control group was treated with apatinib, The observation group received cindilizumab in combination with apatinib, Objective response rate (ORR), disease control rate (DCR) in both groups, The levels of sugar antigen 50 (CA-50), sugar antigen 199 (CA199), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC) were detected by enzyme-linked immunosorbent assay before and after treatment; Record the subsequent prognostic survival in both groups by follow-up, A multivariate Logistic model was established to analyze the independent risk factors affecting patients reaching median OS and PFS. Results: Compared with the control group, the ORR and DCR rates of the observation group were higher (P<0.05). Compared with the control group, the levels of serum CA50, CA199, CEA and SCC in the observation group were lower after treatment (P<0.05). Compared with the control group, the median OS and PFS in the observation group were longer(P<0.05). Multivariate Logistic analysis showed that treatment, CA50, CA199, CEA and SCC were independent risk factors affecting the prognosis and survival of esophageal cancer(P<0.05). Conclusion: The use of immune checkpoint inhibitors and anti- angiogenic drugs for second-line treatment of patients with advanced esophageal cancer can not only reduce the concentration of tumor markers in serum, but also prolong the prognosis and survival of patients, and the therapeutic effect is more significant. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
